Interview with Aihua Pan, Chairman, SinoBioway Group
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Address: PKU Biocity No. 39 ShangDiXi Lu, Haidian, Beijing, P.R. China
Tel: 86 10 8289 0924
SinoBioway Group Co., Ltd. was founded in 1992 and is one of the three major industry groups of Beijing University. It is mainly engaged in bio-industry development and the establishment of bio-economic systems with a focus on investment in three main areas: bio-medicine, bio-agriculture and bio-services. After more than ten years of dedication, the group has become China’s most influential and modern bio-enterprise.
The group now owns three main facilities: Beijing University Biological City, Beijing University Biological Park at Xiamen and Guangzhou Liuxi Biological Bay. Additionally, the group operates multiple holding subsidiaries such as Beijing Sinovac Biotech Co., Ltd., Xiamen Bioway-PKU Biotech Co., Ltd., Guangzhou Weiming Biotech Co., Ltd., Weiming Nature Unity Chinese Medicine Co., Ltd. and Beijing Weiming Kaituo Agricultural Biotech Ltd.
The main products of SinoBioway include an injection of mouse-nerve growth factor (Nobex ®), an inactivated hepatitis A vaccine (Healive ®), a hepatitis B vaccine (Bilive ®), anti-flu vaccines (Anflu ®, Panflu ®, and Panflu.1 ®), as well as hundreds of kinds of Chinese medicinal granules. The group now has established a fairly complete R & D system with centers for: Bio-Pharmaceutical Research, Vaccine Research, National Crop Molecular Design, Bio-Intelligence Research, Bio-Economic Research. It operates various institutions and R & D platforms while employing a group of outstanding research personnel.
Having researched mainly for the bio-economy, biological drugs (generic drugs and peptide drugs), human vaccines, modern Chinese medicine, molecular crop breeding, biomass energy and bio-intelligence technology, the group has achieved a series of major breakthroughs. These include the successful development and production of the world’s first drug treatment of traumatic nerve injury – the “nerve growth factor”, the world’s first “inactivated vaccine targeting SARS virus”, and China’s first “human-use influenza vaccine”. The world’s first influenza A (H1N1) vaccine -Panflu.1 ® was successfully produced on September 3, 2009. The group has initiated the world’s first “bio-economy incubator” (an efficient R & D system of new drugs), established a theoretical system of bio-economy, created an economic bio-restructuring model, and carried out a preliminary study of bio-industry development ideas suitable for China’s national conditions.
SinoBioway has engaged in corporate restructuring and through government guidance has shifted to a market approach. At the moment, the group has formed five industry groups on the basis of existing enterprises which include: vaccines, traditional Chinese medicine, bio-pharmaceuticals, modern agriculture and biological services. Through forming bio-economic systems in the industrial, R & D and financial arena, the group aims to build SinoBioway into a flagship company for the bio-economy era.
vaccines, traditional Chinese medicine, bio-pharmaceuticals
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the…
Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to…
The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial…
Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over…
Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking…
Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese…
Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his…
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China,…
Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio…
Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed…
Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs…
See our Cookie Privacy Policy Here
